Decision summary: Mounjaro is one brand of tirzepatide, a once-weekly prescription injection acting at GIP and GLP‑1 receptors. In eligible trial participants who also received lifestyle support, average weight loss was substantial. It is not appropriate for everyone. A sound decision asks four questions: is there an approved indication, what are your personal risks, how will side effects be managed, and what is the long-term plan?
This is educational material, not an advertisement, prescription or promise of treatment. A PMC consultation is an assessment and does not guarantee that tirzepatide will be prescribed or available.
1. What is Mounjaro?
Tirzepatide is injected once weekly
It is a long-acting subcutaneous medicine. Mounjaro is a brand name rather than a generic “slimming course”; use must follow the locally approved label and an individual prescription.
Dual GIP and GLP‑1 action
The medicine supports glucose-dependent insulin response, influences glucagon, slows gastric emptying and may reduce appetite. These effects can support weight and glucose management but also explain many gastrointestinal adverse effects.
How it differs from semaglutide and liraglutide
Semaglutide (in Ozempic/Wegovy) acts at GLP‑1 and is weekly; liraglutide (in Saxenda) acts at GLP‑1 and is generally daily. Brand-specific indications are not interchangeable.
Mounjaro and Zepbound
Both contain tirzepatide, while approved uses and labels differ by market. The product registered in Thailand and its current indication must be checked at the time of care.
2. How much weight loss did trials report?
SURMOUNT‑1 at 72 weeks
Mean changes were −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg, versus −3.1% with placebo. Participants had obesity or overweight with a complication, did not have diabetes, and received lifestyle intervention. These are group averages, not an individual forecast.
SURMOUNT‑5 versus semaglutide
At 72 weeks, mean loss was about 20.2% with maximally tolerated tirzepatide and 13.7% with maximally tolerated semaglutide under trial conditions. Suitability and tolerability remain more important than choosing by headline percentage.
Beyond weight
Waist circumference, glucose, blood pressure and selected lipid measures improved in trials. Existing medicines may need review as physiology changes; they should never be stopped without guidance.
3. Who may be suitable—and who should not use it?
BMI and Asian risk thresholds
Medication is generally considered at obesity thresholds, or overweight with weight-related disease. Asian populations may develop metabolic risk at a lower BMI. Waist, comorbidities, previous interventions and personal goals matter alongside BMI.
Contraindications and cautions
- US labelling contraindicates use with personal/family MTC, MEN2 or serious tirzepatide hypersensitivity.
- Weight-loss treatment should not be used in pregnancy; pregnancy planning and breastfeeding require medical review.
- Previous pancreatitis, gallbladder disease, severe gastric dysmotility, kidney disease and diabetic retinopathy warrant closer assessment.
- Insulin or sulfonylureas may increase hypoglycaemia risk.
Not a cosmetic injection for normal weight
Using prescription medicine without a health indication can expose a person to adverse effects, undernutrition and lean-mass loss without a clear medical benefit.
4. How is tirzepatide used?
Injection site and schedule
It is injected under the skin of the abdomen, thigh or upper arm once weekly, rotating sites. Training must match the exact pen supplied.
Start low and titrate
US labelling starts at 2.5 mg weekly for four weeks, then 5 mg. If needed and tolerated, increases are 2.5 mg no more frequently than every four weeks, to 15 mg maximum. Follow the Thai label and prescription; never self-escalate.
Missed dose
US instructions allow a missed dose within 96 hours; after that it is skipped. Two doses should be at least 72 hours apart. Check with the clinic when uncertain.
Storage
Protect from light and freezing. US labelling allows up to 21 days at no more than 30°C, but a parked vehicle in Phuket can exceed this quickly. Follow the leaflet supplied with your product.
5. Side effects and red flags
Common effects
Nausea, diarrhoea, constipation, vomiting, abdominal discomfort, indigestion and appetite loss are common, especially around escalation. Smaller, lower-fat meals and hydration may help.
Seek urgent assessment
- Severe, persistent abdominal pain, especially radiating to the back
- Repeated vomiting, low urine output, dizziness or dehydration
- Right-upper abdominal pain, fever or jaundice
- Breathing difficulty, facial swelling or severe allergy
Lean mass and “Ozempic face”
The popular phrase is not a diagnosis and is not specific to one medicine. Rapid loss can reduce facial fat and lean mass; adequate nutrition and resistance exercise are part of safer care.
Oral contraception
US labelling advises non-oral contraception or an added barrier for four weeks after initiation and each dose escalation because delayed gastric emptying can reduce oral contraceptive effectiveness.
6. What happens after stopping?
SURMOUNT‑4
After a 36-week lead-in mean loss of 20.9%, participants switched to placebo regained 14.0% on average over the randomised 52 weeks, while continued treatment produced a further 5.5% mean loss. Obesity often requires chronic management.
Long-term use is a shared decision
Benefit, adverse effects, access, quality of life and patient preference should be reviewed. A stopping plan should include nutrition, activity, monitoring and an agreed response to regain.
7. Lifestyle protects the quality of weight loss
Prioritise protein and nutrient density
Lower appetite can make inadequate intake easy. Include protein and nutrient-rich food at meals, with individual adjustment for kidney disease or other restrictions.
Use resistance exercise
Strength work adapted to ability helps preserve function and lean mass. Combine it with aerobic activity and track strength and waist as well as weight.
Reduce digestive symptoms
- Eat slowly and stop at comfortable fullness
- Use smaller meals
- Sip fluids regularly
- Avoid heavy fried meals and alcohol when symptomatic
8. Using Mounjaro responsibly in Thailand
Prescription medicine, not a beauty product
Thai rules restrict public promotion of controlled prescription medicines. This page provides health information without prices, purchase links or a promise to supply.
Avoid counterfeit and heat-damaged pens
Unverified online products may be counterfeit, the wrong strength, contaminated or improperly stored. Use a lawful clinical/pharmacy pathway and verify registration and packaging.
Disclose PrEP, ART, hormones and all oral medicines
Delayed gastric emptying and vomiting may affect some oral medicines or adherence. A clinician or pharmacist should review the exact drug and dose rather than assuming a class-wide interaction.
9. Frequently asked questions
How many kilograms should I lose in month one?
There is no standard target. The first month commonly prioritises tolerability at the starting dose.
Can someone without diabetes use it?
Some tirzepatide products have weight-management indications in some countries for eligible people without diabetes. Thai registration and individual eligibility must be checked.
Can I drink alcohol?
Alcohol may worsen nausea, dehydration or hypoglycaemia risk in some people. Avoid it, especially during initiation or escalation, unless your clinician advises otherwise.
Mounjaro or Ozempic?
Neither is universally better. Indication, comorbidities, other medicines, tolerability and access determine the choice.
Can I inject at home?
Only after receiving a legitimate prescription and device training. Do not repeat a dose by guesswork after a device problem.
10. Prepare for a useful medical consultation
Bring your medicine and supplement list, recent results, weight history, previous interventions, and pregnancy/contraception information. The clinician may recommend another pathway when tirzepatide is unsuitable.
Book a PMC assessment and select Laguna, Circle Clock Tower, Phuket Town or Koh Sirey. Booking arranges clinical assessment; it does not guarantee a prescription.
Medical references
- Mounjaro Prescribing Information
- Zepbound Prescribing Information
- SURMOUNT‑1
- SURMOUNT‑5
- SURMOUNT‑4
- Thai FDA advertising FAQ
- FDA: unapproved GLP‑1 products
Reviewed 29 October 2026. General information only; not a diagnosis or personal prescription. Local indications may change.